The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
In addition to having the highest obesity rates, the U.S is currently facing significantly higher prices for several major drugs used for weight loss and other health needs, according to a new KFF analysis of the list prices for semaglutide and tirzepatide drugs.
Semaglutide…has been selected for the second round of Medicare drug price negotiation…Many people are familiar with Ozempic and other drugs like it, use of these drugs has expanded rapidly in recent years, and the list price is high. All of that could focus more attention on this year’s drug price negotiation process….
KFF’s January 2025 Prescription Drug Advertisements Poll looks at the public's experiences with prescription drug advertisements, whether they've talked to a doctor about advertised drugs, and how this has influenced the care they receive.
States expect national Medicaid enrollment to decline by about 4% and state Medicaid spending to rise by 7% in fiscal year (FY) 2025.
This brief examines the two presidential candidates’ records and other recent policy proposals that could inform starkly different directions for the program across key areas, including Affordable Care Act (ACA) Medicaid expansion, financing, eligibility, benefits, and cost-sharing, prescription drugs, long-term services and supports, and managed care.
This brief focuses on the stand-alone Medicare Part D prescription drug plan marketplace and its somewhat uncertain future, in light of recent trends in plan availability and the potential for another year of premium increases in 2026, in part depending on what the Trump administration decides to do with the temporary Part D premium stabilization demonstration. The brief explains why the stability of the PDP market matters, both for people in traditional Medicare who want prescription drug coverage but also for the viability of traditional Medicare as an option vis a vis Medicare Advantage.
Medicare's New Prescription Drug Benefit: The Voices of People Dually Covered by Medicare and Medicaid This focus group report highlights the kinds of questions, uncertainties, and reactions that dual eligibles have when asked about the impending changes in their drug coverage. Report (.
Toplines -- Kaiser Health Poll Report: Selected Findings on Seniors' Views of the Medicare Prescription Drug Benefit These toplines contain the detailed results from the February 2006 tracking poll on seniors' views toward the new Medicare drug benefit. Survey Toplines (.
describes key characteristics of the organizations that offer the new Medicare drug benefit and analyzes how companies are positioning themselves to attract Medicare enrollees.
This comprehensive survey of people on Medicare, conducted in June and July 2004, assesses their attitudes toward the new Medicare drug law. This chartpack, issued in September 2004, presents additional analysis on the survey data, looking at key findings broken down by income group. Chartpack (.
© 2026 KFF